In this randomized, double-blind, placebo-controlled, multicentre trial, 126 patients between July 5 2007 and July 30 2008 are planned to enroll in randomized into 2 groups from 10 centers: the experimental group and control group (1:1). The code-breaking time estimate is about June 2009. The leader units are Shanghai Chest Hospital Affiliated to Shanghai Jiao-Tong University and Shanghai Changzheng Hospital. Main eligibility criteria were histologically or cytologically proven stage III or IV NSCLC, with an age of 18-75 years. All eligible patients received 1 cycle (21 days) of TC chemotherapy. After chemotherapy, patients with the curative effect reaches above SD or SD were randomized to receive endostar® plus TC or TC alone for 3 cycles. Each 21-day cycle consisted of endostar® 7.5mg/m2 on days 8 to days 21, carboplatin AUC 5 on day 1, and paclitaxel 175 mg/m on day 1. Primary endpoint: time to progression (TTP). Secondary endpoint:Progress Free Survival (PFS).1 year survival rate. objective response(OR), clinical benefit rate(CBR), median survival time (MST), quality of life (QOL) and remission rate of clinical symptom.